CT-2103: A Novel Macromolecular Taxane with Potential Advantages Compared with Conventional Taxanes

This publication has 17 references indexed in Scilit:

• Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
  Journal of Clinical Oncology, 2004
• Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [XYOTAX™], a Biodegradable Polymeric Drug Conjugate
  Published by Springer Nature ,2004
• 566 Phase 1 study of CT-2103/carboplatin in patients with solid tumors
  European Journal of Cancer Supplements, 2003
• 806 Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX) in patients with non-small-cell lung cancer who are > 69 years of age or who have performance status (PS) = 2
  European Journal of Cancer Supplements, 2003
• 554 Phase 1 study of CT-2103/cisplatin in patients with solid tumors
  European Journal of Cancer Supplements, 2003
• The dawning era of polymer therapeutics
  Nature Reviews Drug Discovery, 2003
• Macromolecular Therapeutics
  Clinical Pharmacokinetics, 2003
• Membrane dynamics and the biogenesis of lysosomes (Review)
  Molecular Membrane Biology, 2003
• Cremophor EL
  European Journal Of Cancer, 2001
• Is the multidrug transporter a flippase?
  Trends in Biochemical Sciences, 1992